An interventional study of Wearing the connected watch in Heart Disease, sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Heart Diseases with a site in France — 29 open to participants now, 37 under way, 5 of them phase 3. Heart Diseases · France.
Among the 126 studies in Heart Diseases with a site in France, this one is the 58th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2025, is one of 48 with no phase, reaches primary completion later than 12 of the 36 other live ones, and was the 113th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →29 of the 126 studies in Heart Diseases with a site in France are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in France, United States, Brazil and 6 more countries
Ages 6+
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
Kiniksa Pharmaceuticals International, plc · Sites in France, United States, Canada and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in France, Argentina, Australia and 35 more countries
Ages 50+
Lexeo Therapeutics · Sites in France, United States, Brazil and 5 more countries
Ages 6+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 22 · Phase 4 3
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 81 is below the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 240 across the 79 interventional studies, 375 across the 46 observational. Of the 76 that completed or were terminated, 23 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 126 have an industry lead sponsor. The 10 most frequent:
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône has 1 study filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Heart Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06420960L'hôpital Nord-Ouest - Villefranche Villefranche sur SaôneDiagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG | 2027-01-18 |
| NCT07888218Central Hospital, Nancy, FranceReplacing Spatial Filtering With Deep-learning Noise Reduction | 2027-01-23 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 126 studies in Heart Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Palpitations are a frequent reason for consultation (16% of total volume) and management in the emergency department.
Conventional diagnostic management in our establishment is based on a 48-hour external ECG holter, combined with a stress test if symptoms are triggered by physical activity.
The diagnostic difficulty lies in the frequency and duration of this transient symptom. At the time of consultation, the patient is often asymptomatic. The initial strategy is to demonstrate an electrocardiographic trace during the attack, in order to adapt management to the chosen etiology.
The HOLTER ECG is the gold standard, but it is not very cost-effective due to the infrequent and random nature of the onset of symptoms.
The advent of accessible connected tools such as connected watches seems to be an interesting alternative for acquiring a per-critical trace of symptoms. They are widely adopted by the general population, with ease of use by the individual and long monitoring times.
The main aim of the study is to establish the diagnostic cost-effectiveness of one or other of the two diagnostic strategies (rate of identification of the causal arrhythmia) at 6 months from the cardiological consultation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study
Device: Wearing the connected watch
All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study
Device: Wearing the connected watch
All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address. They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance.
Rate of diagnostic profitability of the connected watch compared with the conventional procedure (48-hour ECG Holter).
The investigators will compare the diagnostic performance of the connected watch with the HOLTER ECG, by identifying a symptomatic arrhythmia, , in the purpose of a faster and adapted cardiological management.
Time frame: at 6 months or when the watch is returned, whether a diagnosis has been made or whether there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.
Type of diagnosis recorded.
A diagnosis is defined by the documentation of an objective cardiac arrhythmia (focal atrial tachycardia/atrial fibrillation HR \>110 bpm/atrial fibrillation HR\<110 bpm/atrial flutter/junctional tachycardia/sustained or non-sustained ventricular tachycardia/peak tachycardia/sinus tachycardia/ventricular fibrillation/high-degree conduction disorder) concomitant with the symptomatology motivating the initial consultation.
Time frame: at 6 months or when the watch is returned if a diagnosis has been made.
Rate of concomitant diagnoses with either device
Symptomatic objective cardiac arrythmia recorded with the smarwatch, the HOLTER or the both
Time frame: at 6 months or when the watch is returned if a diagnosis has been made.
Rate of causal non-rhythmological diagnosis (symptoms without pathological per-critical ECG tracing)
Rate of ECGs failing to explain symptomatology (no ECG abnormality detected ECG) Time Frame : at 6 months or when the watch is returned if a diagnosis has been made or if there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.
Time frame: at 6 months or when the watch is returned if a diagnosis has been made or if there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.
Medical/paramedical time per diagnosis and per patient
Fitting of holter ECG equipment, handover of watch and explanation of how it works, analysis of holter/ ECG tracings, reconsultation)
Time frame: at 6 months or when the watch is returned, whether a diagnosis has been made or whether there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.
Plan to share: Undecided — Confidentiality and Privacy: Sharing IPD data could compromise the confidentiality and privacy of participants. Individual data, even anonymized, could potentially be used to identify individuals, particularly in the case of small cohorts or sensitive data. Data Sensitivity: IPD data includes sensitive health information. Sharing such data is subject to strict data protection regulations and requires additional measures to ensure security and confidentiality. Resources and Costs: Sharing IPD data requires additional resources for anonymization, management, and data provision. We do not have the necessary resources to perform these tasks due to our limited budget.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 21 months is below that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône